logo
  

GEA Presents Growth Strategy For Next Five Years

GEA Group (GEAGF.PK,GEAGY.PK) presented its "Mission 26" strategy in London as part of its Capital Markets Day.

The strategy sets ambitious financial targets for 2026. Organic sales growth of 4.0 to 6.0 percent per year is expected, leading to sales of around 6 billion euros compared to 4.635 billion euros in fiscal year 2020. The EBITDA margin before restructuring expenses is projected to grow to a record level of more than 15 percent.

Capital expenditure (CAPEX) is projected to be around 200 million euros annually until 2026.

Sales of new machines are expected to grow by 4.0 to 5.0 percent per year until 2026.

GEA confirmed the guidance for fiscal year 2021 that was raised in July 2021. Organic growth of 5.0 to 7.0 percent is expected for revenue. EBITDA before restructuring expenses at constant exchange rates is anticipated to be in a range between 600 million euros and 630 million euros.

GEA has confirmed fiscal year 2022 outlook. Group revenue is expected to grow by an average of 2.0 to 3.0 percent annually from 2019 until 2022, the EBITDA margin before restructuring expenses is to increase to a target corridor of 12.5 to 13.5 percent.

In June 2021, GEA presented its interim targets for reducing its own greenhouse gas emissions alongside its net zero ambition for 2040. Greenhouse gas emissions in Scopes 1 and 2 are to be reduced by 60 percent and in Scope 3 by 18 percent by 2030.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Starbucks has dropped its vaccine or weekly test requirement against Covid-19 for U.S. employees in the wake of last week's U.S. Supreme Court ruling. The court, in a 6-3 vote, has blocked President Joe Biden's vaccine-or-test mandate for private companies with 100 or more employees. However, it allowed the vaccine mandate to stand for certain health care workers. Mylan Pharmaceuticals Inc., affiliated to healthcare company Viatris Inc., is recalling one batch of its non-interchangeable Semglee (insulin glargine injection), 100 units/ml (U-100), 3mL prefilled pens due to the potential for a missing label, the U.S. Food and Drug Administration said. Mushie & Co, LLC is recalling FRIGG Silicone Pacifiers citing choking risk, the U.S. Consumer Product Safety Commission said. The recall involves about 333,725 units of FRIGG silicone pacifiers that came in two designs: Classic and Daisy. According to the agency, the base of the silicone nipple has a fine slit that can cause the nipple to detach from the plastic shield, posing a choking hazard.
RELATED NEWS
Follow RTT